title: Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
abstract: Site-specific conjugation technologies enable the production of homogeneous antibody-drug conjugates (ADCs) with improved therapeutic indices compared to conventional ADCs. However, current site-specific conjugation methods can only attach one type of drug to a single antibody. Given the emergence of acquired resistance to current ADCs, arming single antibodies with different drugs may provide an attractive option in the development of next-generation ADCs. Here, we describe a site-specific dual conjugation strategy as a platform for dual warhead ADCs.
authors.forename: Xiuling
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Cell and Molecular Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
authors.forename: James T
authors.initials: JT
authors.lastname: Patterson
authors.forename: Mohosin
authors.initials: M
authors.lastname: Sarkar
authors.forename: Lee
authors.initials: L
authors.lastname: Pedzisa
authors.forename: Thomas
authors.initials: T
authors.lastname: Kodadek
authors.forename: William R
authors.initials: WR
authors.lastname: Roush
authors.forename: Christoph
authors.initials: C
authors.lastname: Rader
mesh_terms: D045744:Cell Line, Tumor; D003545:Cysteine / Q000737:chemistry*; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry*; D017279:Selenocysteine / Q000737:chemistry*; D000068878:Trastuzumab / Q000737:chemistry*
chemical_list: D018796:Immunoconjugates; D017279:Selenocysteine; D003545:Cysteine; D000068878:Trastuzumab